Announcements Trials
Browse Landscape

Phase

Phase 4 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other 1Gastrointestinal 1

Conditions

Breast Neoplasms 2Psoriasis 1Prostatic Neoplasms 1Precancerous Conditions 1Paget's Disease, Mammary 1Osteoarthritis 1Obesity 1Neoplasms 1Neoplasm, Residual 1Fatigue 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Intraductal, Noninfiltrating 1Cancer Cachexia 1Breast Carcinoma In Situ 1Barrett Esophagus 1Autoimmune Diseases 1Arthritis, Rheumatoid 1Aggressive Periodontitis 1

Interventions

Metformin 7Exenatide 4Vitamin D 2Sugars 2Resistance Training 2penclomedine 1licogliflozin 1exemestane 1dapagliflozin 1bupropion hydrochloride, naltrexone hydrochoride drug combination 1Weight Reduction Programs 1Therapeutics 1Testosterone 1Taxes 1Tamoxifen 1TOPS 1Surveys and Questionnaires 1Sugammadex 1Sodium-Glucose Transporter 2 Inhibitors 1Radiotherapy, Intensity-Modulated 1Radiotherapy, Conformal 1Qsymia 1Progesterone 1Paclitaxel 1Observation 1Nutrition Assessment 1Naltrexone 1Methods 1Letrozole 1Jogging 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Obesity × Docosahexaenoic Acids × Clear all
NCT01733147 2022-01-11

Modulation of Esophageal Inflammation in Barrett's Esophagus by Omega-3 Fatty Acids

Mayo Clinic

Phase 4 Completed
60 enrolled 6 charts
GastrointestinalOther

Barrett Esophagus, Obesity

Data powered by HemOnc (CC BY 4.0) Colophon âš¡